A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

University of California San Francisco (UCSF)

Status and phase: Completed; Phase 4

Conditions: Frontotemporal Lobar Degeneration

Treatments: Drug: Memantine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00187525

NAM-02A

Details and patient eligibility

About

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neary et al. Criteria for Frontotemporal Lobar Degeneration
• Age 40 -80
• CDR < 3 or MMSE > 15
• English Speaking
• Study Partner

Exclusion criteria

• Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)